Opinion

Video

Key Factors in Gene Vector Selection

Jessica Nance, MD, MS, discusses maximizing gene therapy efficiency by selecting vectors for gene size, tissue targeting, and low exposure, and focusing on precise promoters for expression.

This is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, MBA; Jessica Nance, MD, MS; Kimberly C. Chen, DO, MSHLM; Emma Ciafaloni, MD, FAAN; and Mary Pak, MD, FACP.

Nance offers a comprehensive insight into the significance of vectors in gene therapy delivery. Highlighting 3 key components—vector selection, tissue targeting, and promoter design—she emphasizes the importance of efficient gene transfer and minimal immune response. Vectors must accommodate the gene size, target specific tissues, and evade preexisting immunity. Utilizing viruses as vectors capitalizes on their inherent cellular entry mechanisms while minimizing immune recognition. Nance’s explanation underscores the meticulous engineering behind vectors to ensure precise gene expression in desired tissues, enhancing therapeutic efficacy. Haumschild acknowledges the importance of vector specificity in optimizing therapeutic value while minimizing immune responses, highlighting the delicate balance between scientific innovation and clinical application in gene therapy.

Video synopsis is AI-generated and reviewed by AJMC® editorial staff.

Related Videos
Justin Oldham, MD, MS, an expert on IPF
4 KOLs are featured in this series
4 KOLs are featured in this series
Justin Oldham, MD, MS, an expert on IPF
Justin Oldham, MD, MS, an expert on IPF
Justin Oldham, MD, MS, an expert on IPF
1 KOL is featured in this series.
5 KOLs are featured in this series.
4 KOLs are featured in this series
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo